THERAPY DOSSIER · th-92143950b203

XPro1595 (dominant-negative soluble TNF inhibitor); comparator biologic etanercept

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: Not recorded
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: XPro1595; XENP-1595; INB03; DN-TNF; Quellor; Livnate
Note: Not recorded

Clinical trials 5

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT04370236 ↗PHASE2/PHASE3terminated

Placebo-Controlled Trial of INB03 (pegipanermin) in Pulmonary Complications From COVID-19

COVID-19

Enrolment: 79 · Results not recorded

NCT05318976 ↗PHASE2completed

Randomized Placebo-Controlled Double-Blind Study of XPro1595 in Early Alzheimer's Disease With Biomarkers of Inflammation

Alzheimer Disease · Mild Cognitive Impairment

Enrolment: 207 · Results not recorded

NCT05321498 ↗PHASE2withdrawn

Phase 2 Study of XPro1595 in Mild Cognitive Impairment With Biomarkers of Inflammation

Mild Cognitive Impairment · Alzheimer Disease

Enrolment: 0 · Results not recorded

NCT05522387 ↗PHASE2terminated

Open Label Extension of XPro1595 in Alzheimer's Disease Patients Completing a Phase 1 or Phase 2 Study

Alzheimer Disease

Enrolment: 11 · Results not recorded

NCT03943264 ↗PHASE1completed

Phase 1b Open-Label Dose-Identification Study of XPro1595 in Alzheimer's Disease With Biomarkers of Inflammation

Alzheimer Disease

Enrolment: 20 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25204558 ↗2014Mixed findings

Central but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in mice.

MouseSpinal cord injuryContusionC57BL/6Femalen = Systemic study 12 mice per treatment group; central study g…Central intrathecal infusion to the lesion epicentre (osmotic pump) or systemic subcutaneous injectionCentral: XPro1595 2.5 mg/mL delivered at 1 microlitre per h…First administration 30 minutes after spinal cord injury

Model: Moderate contusion spinal cord injury at T8 to T10 by impactor after laminectomy

Systemic subcutaneous XPro1595 or etanercept produced no discernible improvement in locomotor recovery. Central infusion of XPro1595 improved locomotor function, reduced anxiety-related behaviour and reduced tissue damage with preserved myelin basic protein, whereas central etanercept had no therap…

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…